BAY1003803 Formulation Comparison in Open Psoriasis Plaque Test

Inclusion Criteria: * Male and female (non-childbearing potential) volunteer with stable plaque-type psoriasis, but otherwise healthy * Age: 18-64 years Exclusion Criteria: * Severe disease within the last 4 weeks prior to the first study drug administration as determined by the investigator * Any topical antipsoriatics on plaques potentially to be treated in this trial (including corticosteroids, vitamin D analogues, immunomodulators, retinoids, dithranol and tar, except for salicylic acid (Pretreatment) in the 4 weeks before first treatment and/or planned during the trial, except for allowed topical treatment on the face, ears and scalp * Systemic treatment depending on kind of treatment within 4 weeks and 6 months prior and/or planned during the trial * Treatment with concomitant medication that may affect and provoke or aggravate psoriasis, e.g. antimalarial drugs, lithium, beta-blockers or angiotensin-converting-enzyme inhibitors (AEC inhibitors) unless on a stable dose for 3 months before study medication initiation * Clinico-chemical parameters of clinically significant deviation